FNY Managed Accounts’s Achillion Pharmaceuticals ACHN Stock Holding History

FNY Managed Accounts’s Portfolio ACHN Stock Details ACHN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-512	Closed	-$7.44K	–	340
2016 Q3	$7.44K	Buy	+512	New	+$4.35K	0.01%	324
2016 Q1	–	Sell	-400	Closed	-$21K	–	418
2015 Q4	$21K	Buy	+400	New	+$3.64K	0.1%	84
2015 Q3	–	Sell	-64	Closed	-$320	–	633
2015 Q2	$320	Sell	64 -111	-63%	-$1.05K	﹤0.01%	444
2015 Q1	$2.19K	Buy	+175	New	+$2.19K	﹤0.01%	311
2014 Q3	–	Sell	-300	Closed	-$6K	–	229
2014 Q2	$6K	Buy	+300	New	+$1.2K	0.02%	76

Other funds holding ACHN

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

FNY Managed Accounts's ACHN Position: Q3 2014 in Review

FNY Managed Accounts sold out of Achillion Pharmaceuticals (ACHN) in Q3 2014, closing a stake of 10,000 shares — an estimated $75.7K sold.

FNY Managed Accounts first reported a position in ACHN in Q2 2014 and held it in 1 quarter. The position peaked at $75.7K in Q2 2014. 161 funds tracked by Wall St. Rank hold ACHN as of Q3 2014.

FNY Managed Accounts reported no remaining Achillion Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
FNY Managed Accounts sold 10,000 Achillion Pharmaceuticals shares in Q3 2014, an estimated $75.7K.
FNY Managed Accounts first reported a position in Achillion Pharmaceuticals in Q2 2014 and held it in 1 quarter.
FNY Managed Accounts's Achillion Pharmaceuticals position peaked at $75.7K in Q2 2014.
161 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q3 2014.

Based on FNY Managed Accounts's 13F filing for Q3 2014, filed 16 Oct 2014.